Medication Prescribing

It is the first sodium-glucose co-transporter 2 inhibitor to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.

It is the first sodium-glucose co-transporter 2 inhibitor to be approved to treat adults with New York Heart Association’s functional class II-IV heart failure with reduced ejection fraction.

This roundup of COVID-19 stories includes details on a new serological assay, recommendations for the treatment of patients with diabetes during the pandemic, and an FDA warning on the use of...

The US Food and Drug Administration have approved the first generic of albuterol sulfate inhaler, for the treatment and prevention of bronchospasm in patients with reversible obstructive airway disease who...

The US Food and Drug Administration has announced that it is requesting that manufacturers withdraw all prescription and over-the-counter ranitidine drugs (Zantac) immediately.

A roundup of COVID-19 news, including potential treatment options, new guidance from the CDC and IDSA, and statements from the FDA on testing and the use of NSAIDs.

The US Food and Drug Administration have approved a supplemental application for a hepatitis C treatment option to include treatment of hepatitis C virus (HCV) in children aged 6 years and older.

The new safety labeling changes approved by the FDA address the use of SGLT2 inhibitors prior to surgery.

The new safety labeling changes approved by the FDA address the use of SGLT2 inhibitors prior to surgery.

The new safety labeling changes approved by the FDA address the use of SGLT2 inhibitors prior to surgery.